+

WO1996013275A1 - Procedes et produits permettant d'ameliorer les reactions immunitaires - Google Patents

Procedes et produits permettant d'ameliorer les reactions immunitaires Download PDF

Info

Publication number
WO1996013275A1
WO1996013275A1 PCT/US1995/013895 US9513895W WO9613275A1 WO 1996013275 A1 WO1996013275 A1 WO 1996013275A1 US 9513895 W US9513895 W US 9513895W WO 9613275 A1 WO9613275 A1 WO 9613275A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cytokine
cells
antigen
antigen presenting
Prior art date
Application number
PCT/US1995/013895
Other languages
English (en)
Other versions
WO1996013275A9 (fr
Inventor
David R. Kaplan
Original Assignee
Tkb Associates Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tkb Associates Limited Partnership filed Critical Tkb Associates Limited Partnership
Publication of WO1996013275A1 publication Critical patent/WO1996013275A1/fr
Publication of WO1996013275A9 publication Critical patent/WO1996013275A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2

Definitions

  • the present invention relates to cyto ine related products and methods useful for enhancing immune responses.
  • Inactive B and T lymphocytes are specifically activated when their clonally distributed receptors are exposed and bound to a corresponding specific antigen.
  • Cytokines are produced in abundance by a subset of T lymphocytes after the lymphocytes are activated and facilitate the two events that comprise activation of lymphocytes: (1) clonal expansion so that specific lymphocytes increase in frequency; and (2) differentiation so that mechanisms to effect immunity are manufactured by the cell.
  • Interleukin 2 (I -2) is a cytokine that greatly enhances immune responses and that markedly stimulates cell proliferation and differentiation of a variety of different immune cells including T cells, B cells, raacro- phages, monocytes, natural killer cells, and granulocytes
  • IL-2 Conditioned supernatants from lectin-stimulated peripheral blood mononuclear cells were shown to enhance the proliferation of T cells in culture. Later the substance most respon ⁇ sible for this activity was defined as IL-2.
  • the identity of IL-2 was solidified by cloning of the cDNA (T. Taniguchi et al. , Nature, 302:305 (1983) ; R. Devos et al., Nucl . Acids Res . 11:4307 (1983) ; and S. Clark et al . , Proc . Natl . Acad. Sci . USA, 81:2543 (1984)) .
  • IL-2 has been produced in large quantities in bacteria, yeast, insect cells, and eukaryotic cells. Because IL-2 was produced as a purified homogeneous product, the activities seen could be clearly assigned to the molecule and the potent activity of IL-2 in inducing T cell proliferation was confirmed. It was also observed that the cytokine strongly promoted the growth of natural killer cells and markedly enhanced the level of cytotoxicity that both natural killer cells and T lymphocytes exhibited (G. Trinchieri et al . , J " . Exp . Med . , 160:1147 (1984) ; E. Grimm et al. , J. Exp .
  • Vectors directing the expression of IL-2 have been utilized in a murine model for solid tumors.
  • Cultured cell lines that produce tumors upon inoculation into naive mice have been transfected with vectors that encode for the expression of IL-2 and given to mice subcutaneously.
  • the mice injected with unmodified cells produced tumors whereas the IL-2 producing tumor cells did not result in any solid tumors.
  • Animals that received the IL-2 producing tumor cells were able to reject unaltered tumor cells that were subsequently injected and no IL-2 dependent toxicity was observed (B. Gansbacher et al., J. Exp . Med. , 172:1217 (1990)) .
  • IL-2 The capacity of IL-2 to enhance cytotoxicity has been used to justify the intravenous inoculation of tumor patients.
  • the injected cytokine has enhanced anti-tumor immunity and locally injected IL-2 has been shown to be effective in stimulating anti-tumor effects.
  • the direct injection of IL-2 at the site of tumors provides a local concentration of the cytokine, and several investigators have demonstrated tumor regression after injection of IL-2 at the site of tumor growth (G. Cortesina et al. , Cancer, 62:2482 (1988) ; G. Forni et al . , J. Immunol . , 138:4033 (1987) ; R. Steis et al . , Proc . Am. Soc .
  • Some of these techniques involve the transfer of cells for the purpose of inducing immunity and include therapies involving the inoculation of a patient with autologous tumor cells that have been manipulated to enhance their immunogenicity.
  • Tumors have been surgically removed and genetically altered with gene vectors that encode for IL- 1, IL-2, IL-4, IL-7, GM-CSF, allogeneic HLA antigens, B7, or IGF-1 antisense.
  • genetic alteration of tumor cells has made the cells immunogenic and therapies based on these findings are currently in clinical trials.
  • IL-2 in liposomes has also been used to deliver the cytokine to a specific site.
  • the local delivery of liposome formulations of IL-2 gave signifi ⁇ cantly greater anti-tumor effects compared to empty liposomes or to soluble IL-2 and was seen to be superior to systemic inoculation of the cytokine (P. Anderson et al., Cancer Res . , 50:1853 (1990)) .
  • the inclusion of IL-2 in liposomes along with a variety of different immunogens such as the polysaccharide from Pseudomonas aeruginosa (E. Abraham and S. Shah, J. Immunol .
  • Encapsulation of the cytokine produced a marked depot effect when the cytokine was given intrathoracially, subcutaneously, or intraperitoneally.
  • the biodistribution and pharmacokinetics of the drug were greatly influenced by both encapsulation and by route of administration (P. Anderson et al . , J. Immunother. , 12:19 (1992)) .
  • Liposome encapsulated IL-2 maintained higher serum levels than free
  • IL-2 when injected intravenously (M. Joffret et al . , Vaccine, 8:385 (1990) ) .
  • vaccinia viruses have been produced that include IL-2 in an expression cassette so that cells infected with the virus produced IL-2 locally (C. Flexner et al . , Nature, 330:259 (1987) ; and I. Ramshaw et al. , Nature, 329:545 (1987)) .
  • the recombinant vaccinia virus was more effective than the parental virus in acting as a vaccine in immunodeficient mice and IL.-2 dependent toxicity was not observed.
  • Another method that co-localizes the cytokine with antigen for vaccination involves the production of a chimeric protein which includes both an IL-2 domain and an antigen domain.
  • a fusion protein consisting of a fully functional IL-2 domain and an epitopically intact herpes simplex virus type 1 glycoprotein D domain has been produced (S. Hinuma et al. , FEBS, 288:138 (1991)) .
  • This fusion protein elicited high titers of specific antibodies and strong cell-mediated immunity without any adjuvants.
  • a fusion protein consisting of both IL-2 and an immuno- globulin chain specific for carcinoma cells has also been produced (H. Fell et al. , J. Immunol . , 146:2446 (1991)) .
  • the activity of the IL-2 and the immunoglobulin remained intact in the chimeric protein and consequently it enhanced the in vitro cytotoxic destruction of tumor cells expressing the relevant antigen.
  • IL-2 Since recombinant IL-2 is poorly soluble at neutral pH and has a short half-life in serum, investigators have chemically modified IL-2 with an active ester of polyethylene glycol (M. Knauf et al . , J “ . Biol . Chem . ; 263:15064 (1988)) . This modification did not alter the molecule's capacity to induce T cell proliferation or to enhance cytotoxicity. However, its serum half-life was greatly increased and its capacity to inhibit the growth of a sarcoma cell line in mice was likewise increased. Polyethylene glycol modified IL-2 also reduced the immuno- genicity of the cytokine (N. Katre, J. Immunol . , 144:209 (1990) ) .
  • Polyethylene glycol modified IL-2 has been injected directly into tumors instead of using an intra- venous route of delivery and the conjugated IL-2 both caused tumor regression and induced the development of specific immunity against the tumor that was transferred to naive animals by lymphocytes (L. Balemans et al., Cane . Immunol . Immonother. , 37:7 (1993)) .
  • IL-2 has been bound to solid phase Sepharose beads via a standard chemical reaction for covalent coupling in order to assess the potential bioactivity of IL-2 in vitro.
  • the IL-2 was spontaneously released into culture medium in active form during short- term incubation and the release was dependent upon the availability of soluble protein in the incubation medium as well as the incubation temperature. .Id.
  • IL-2 coupled to polystyrene beads to form a solid phase of the cytokine was able to increase the cytotoxic activity of rat spleen cells in vitro and a single injection of IL-2 coupled beads into the peritoneal cavities of normal rats resulted in the jLn vivo activation of cytotoxicity of peritoneal exudate cells. (Edward D. Crum et al. , Cancer Research, 51:875-879 (1991)) .
  • IL-2 coupled beads were mixed with methylcholanthrene-induced Mc7 or Mcl07 sarcoma cells and injected into normal syngeneic Wistar rats, the growth of the tumor was suppressed. Id.
  • the present invention concerns products and methods for enhancing immune responses and is based on the discovery that immune responses may be enhanced by adsor ⁇ bing a cytokine to an antigen presenting cell.
  • the adsorption procedure involves incubating cytokine with cell surfaces either in the presence or absence of proteins .
  • Enhancement of immune responses may be achieved through the delivery of a powerful immunostimulatory molecule, such as IL-2, to the site of activation of the immune response by adsorption of the cytokine to the cell surface of the appropriate antigen presenting cell.
  • cell For tumor immunotherapy that cell would be the tumor cell or a tumor cell fused with an antigen presenting cell and for vaccines that cell would be an antigen presenting cell exposed to the relevant antigen such as influenza or tetanus toxoid. Cytokine can also be adsorbed to a T cell that functions not as an antigen presenting cell but is used for adoptive immunotherapy.
  • the present invention features a method for enhancing an immune response by exposing an immune cell to an antigen presenting cell having adsorbed cytokine.
  • enhancing is meant increasing in any way and specifically includes both promoting a pre-existing immune response and generating a new immune response where none existed before. Specific examples of how enhancing an immune response could be measured would vary depending upon the particular immune response, but may include detecting the number of T-cells, B-cells, natural killer cells, monocytes, or granulocytes, the concentration of circulating antibodies or observing certain clinical conditions associated with an immune response.
  • Immune response is the response of the whole or part of an immune system of an organism, i.e.. cellular and humoral systems . in vivo or .in vitro.
  • the immune response is either the proliferation or differentiation of a cell selected from the group that consists of T-lymphocytes, B-lymphocytes, natural killer cells, monocytes and granulocytes.
  • Proliferation is clonal expansion of a cell line such that there is an increase in the frequency or number of cells by cell division, or growth such that there is an increase in cell size.
  • the rate of cell proliferation may be measured by counting the number of cells produced in a given unit of time. Differentiation encompasses changes by which cells manufacture mechanisms to effect immunity through a humoral or cellular response.
  • T-lymphocytes are thymus-derived lymphocytes that are capable of inducing a cell-mediated immune response. Examples of T-lymphocytes include helper T-cells, suppressor T-cells and cytotoxic T-cells. B-lymphocytes are Ig + , Thy " lymphocytes that are capable of inducing a humoral antibody response .
  • Natural killer cells are lymphocyte-like cell that kills antibody- coated eukaryotic cells and can also kill a variety of tumor and virus-infected cells in culture in the absence of an antibody.
  • Monocytes are nonlymphoid cells, in particular a type of white blood cell that become tissue macrophages, which phagocytose and digest invading microorganisms, foreign bodies, and senescent cells.
  • Granulocytes are nonlymphoid cells, in particular a type of white blood cell that is filled with granules containing degradative enzymes that are secreted as part of an immune response.
  • exposing is meant creating conditions either in vitro or .in vivo in which an immune cell is brought into close proximity to a cytokine adsorbed antigen presenting cell such that cytokine is released from the antigen presenting cell and can interact with receptors on the immune cell.
  • An immune cell is a cell that is part of an organism's immune system and includes B lymphocytes, T lymphocytes, natural killer cells, monocytes and granulocytes.
  • the immune cell is a peripheral blood mononuclear cell.
  • cytokine is meant a molecule which facilitates both proliferation and differentiation of immune cells.
  • the cytokine may be IL-2 or self-associated IL-2.
  • Other cytokines include but are not limited to: II--1, IL-4, IL- 5, IL-6, IL-7, IL-10, IL-12 and gamma interferon.
  • cytokine linked to the surface of the antigen presenting cell, for example either by association with a portion of a cytokine receptor complex, via another cytokine binding molecule, via intercalation into the lipid bilayer of the cell or via self-association with bound cytokine.
  • the cytokine may be adsorbed by incu- bating cells, preferably at concentrations ranging from 10 6 / ⁇ to 50 x 10 6 /ml, most preferably 10 x 10 6 /ml, in media containing cytokine, preferably between 100-10,000 nM of recombinant cytokine (e.g. , IL-2) .
  • Adsorption is a process where the cytokine contacts the cell surface of the antigen presenting cell on the extracellular side of the cell membrane, in contrast to intracellular delivery of the cytokine to the cell surface. Adsorption is preferably carried out in vitro.
  • IL-2 some means of adsorption are via an alpha chain of an IL-2 receptor complex or via other IL-2 binding molecules. Self-association of the IL-2 molecule may occur upon binding or adsorption. Adsorption via the alpha chain can be distinguished from an alpha chain independent mechanism (i.e. , by other IL-2 binding molecules) by sensitivity to treatment with acid, which strips IL-2 from the cells expressing the alpha chain but not the cells which do not express the alpha chain. These mechanisms may also be distinguished by the binding of biotinylated or iodinated IL-2 which binds to the cells expressing the alpha chain but not to cells that do not express the alpha chain. Binding of IL-2 to cells that do not express the alpha chain is sensitive to treatment with trypsin or -galactosidase indicating that binding is dependent on glycoproteins on the cell surface.
  • An antigen presenting cell is any cell capable of presenting antigen to an immune cell so as to initiate or modulate (enhance or diminish) an immune response.
  • conventional antigen presenting cells include B-cells, dendritic cells, macrophages, and endothelial cells.
  • the immune response may be enhanced by the localized slow release of the cytokine. Localized slow release is a mechanism for delivery to an immune cell of cytokine derived from the surface of an antigen presenting cell that is positioned in close proximity to the immune cell and occurs over an extended period of time. For example, over a period of days at 37°C in culture. .In vivo, release would be at least over a period of several days.
  • antigen is meant a molecule which participates in the induction or modulation of an immune response through determinant groups that can interact with specific receptors for the antigen.
  • antigens include: fungal antigens, bacterial antigens, parasitic antigens, viral antigens, allogeneic antigens, a xenogeneic antigens and an autologous tumor antigens, including antigens from human immunodeficiency virus, hepatitis B virus, and antigens from allogeneic or xenogeneic tissue.
  • allogeneic is meant from a genetically different member of the same species.
  • xenogeneic is meant from a member of a different species.
  • autologous tumor antigen is meant a tumor antigen derived from the same tumor that is in a patient.
  • the method involves exposure of the immune cell to the antigen presenting cell in vivo.
  • the immune cell may be a peripheral blood mononuclear cell
  • the antigen presenting cell may be a B cell
  • tumor cell e.g.. an autologous tumor cell
  • dendri- tic cell e.g. an autologous tumor cell
  • monocytic cell e.g. an autologous tumor cell
  • the cytokine may be IL-2, a self-associated cytokine, self-associated IL-2, or a mixture of IL-2 and non-IL-2 cytokines.
  • Peripheral blood mononuclear cells include lymphocytes and monocytes.
  • B cell is meant a cell that has the potential to produce immunoglobulin.
  • tumor cell is meant a cell the exhibits unregulated growth.
  • autologous tumor cell is meant a tumor cell derived from the same tumor that is in a patient.
  • dendritic cell is meant an antigen presenting cell with multiple cytoplasmic extensions circulating in the peripheral blood and expressing Class II MHC molecules.
  • monocytic cell is meant a mononuclear phagocytic cell circulating in the blood and expressing Class II MHC molecules and CD14.
  • Epstein-Barr virus transformed B cell is meant a B cell immortalized by infection with the Epstein-Barr virus.
  • endothelial cell is meant a cell lining a vascular space.
  • IL-2 is interleukin 2 and encompasses all or any portion of the molecule encoded by the IL-2 gene, and any variation capable of stimulating immune cells.
  • the IL-2 molecule has an approximate molecular weight of 15,000, and is produced by T-cells.
  • the cDNA for IL-2 has been cloned (Taniguichi et al. , Nature, 302:305 (1983) ; Devos et al., Nucl. Acids Res. 11:4307 (1983) ; and Clark et al . , Proc. Natl. Acad. Sci. USA 81:2543 (1984)) .
  • the sequence of IL-2 is hereby incorporated by reference.
  • the local production of interleukin 2 (IL-2) by T lymphocytes acts to enhance the immune response by inducing growth, differ- entiation and/or cytotoxicity of a variety of immune cells.
  • Self-association occurs when two or more molecules of the same type interact with each other so as to noncovalently bind together.
  • the same type is meant that the molecules have the same function.
  • self- associated IL-2 refers to multiple molecules of IL-2 interacting with each other
  • non-IL-2 self-associated cytokines refers to other cytokines that interact with each other.
  • More than one adsorbed cytokine can be present on an antigen* presenting cell.
  • a mixture of more than one cytokine e.g. , IL-2 and non-IL-2 cytokines
  • an antigen presenting cell can be produced.
  • adsorption of IL-2 to the surface of the antigen presenting cell is via an alpha chain of an IL-2 receptor complex, via any other IL-2 binding molecule, via intercalation of into the lipid bilayer of the cell, or via self-association.
  • An IL-2 receptor complex consists of an c. chain and a ⁇ chain.
  • the chain of an IL-2 receptor complex is a 55 kd protein which binds IL-2 with a Kd of approximately 10" 8 M.
  • the ⁇ chain is involved in signal transduction and is not involved with loading IL-2 onto cells. Binding to other IL-2 binding molecules refers to molecules that bind IL-2 other than the chain. Applicant has found that binding of IL-2 to cells can occur independent of the chain.
  • Intercalation into the lipid bilayer is anchoring in the lipid bilayer of the plasma membrane that is based on non-specific hydrophobic interacts and does not involve specific binding to proteins.
  • Binding by self-association involves binding of additional cytokine molecules to cytokine molecules already bound to an antigen presenting cell.
  • the mole ⁇ cules already bound may have become bound by any of the discussed methods, including self-association.
  • cytokine adsorbed antigen presenting cell may be also provided to immunocompromised patients.
  • Immunocompromised is meant a patient with an abnormality in the immune system, such that the ability of the immune system to generate a response is diminished. Immunocompromised patients may be identified, for example, by reduced white blood counts and other techniques well- known in the art.
  • the invention features an artificial antigen presenting cell having adsorbed cytokine.
  • artificial antigen presenting cell is meant an antigen presenting cell that does not have cytokine naturally bound to its surface or the cytokine is bound in different manner than occurs in nature or the cytokine is bound at greater amounts than naturally occurs on that cell.
  • the cell has been manipulated in vitro to load the cytokine onto the cell surface.
  • the present invention also features methods for producing an antigen presenting cell having cytokine adsorbed by utilizing the process of adsorption.
  • Adsorption includes binding of cytokine to a cytokine receptor on the cell surface, binding of cytokine to any cytokine binding molecule on the cell surface, intercalation of the cytokine into the lipid bilayer of the cell, and self-association of the cytokine.
  • the invention features a method for enhancing immune response by promoting the self- association of IL-2.
  • promoting self-association of IL-2 incubating the cells with IL-2 under conditions that would favor self-association such as concentrations of IL-2 in the self-associating range of from 100 nM to 10,000 nM. Additionally, it may be possible to further promote self- association by changing the primary sequence of IL-2.
  • the invention features a method for adoptive im unotherapy comprising adsorbing IL-2 onto an activated T cell and introducing the T cell into a patient.
  • An activated T-cell is a T-cell specific for an antigen, such as a tumor or a virus.
  • Adsorption of IL-2 onto the T cell is carried out by using any of the described adsorption procedures.
  • Introduction into a patient of the cytokine adsorbed activated T cell is by standard methods known by those who practice the art .
  • Adoptive immunotherapy involves the introduction of activated T-cells into a patient so as to enhance the immune response of the patient. Since T cells are depen ⁇ dent on IL-2 for their survival, pre-loading of these cells with IL-2 prior to inoculation into a patient should increase their survival jLn vivo and thus increase their capacity to mediate immunity n vivo.
  • One advantage of the present invention is that it enhances the capacity of cells to vaccinate individuals to selected antigens such as influenza or tetanus toxoid. Adsorption of cytokine to cells that have been pulsed with antigen or antigenic peptides will permit greater immunogenic potential.
  • cytokine cytokine
  • cytokines such as IL-2
  • IL-2 do not naturally circulate systemically, but are produced physiologically for local consumption.
  • the therapeutic potential of intravenous IL-2 therapy has been considerably restricted by the extraordinary toxicity that is associated with its systemic inoculation (S. Rosenberg et al., N. Engl . J. Med. , 316:889 (1987); W. Urba et al. , Cancer Res . , 50:185 (1990); and K. Margolin et al . , J. Clin . Oncol . , 7:484 (1989)) .
  • Intravenous injections of IL-2 for treatment of patients with solid tumors is limited by the dose of cytokine that can be safely given.
  • IL-2 causes a vascular leak syndrome that can lead to severe hypotension and consequently systemic delivery of the cytokine can be life-threatening.
  • systemic levels of IL-2 there are multiple other serious side effects of systemic levels of IL-2 that have hampered the development of clinical cytokine treatments.
  • one advantage is that the present invention overcomes the problem of systemic toxicity by local delivery of the molecule. Moreover, since delivery is specifically localized to the surface of the cell that bears the antigenic peptides, it is expected that there is greater specificity in the immune response that is elicited. In addition, since release is from a cell localized at the site at which the immune response is generated, levels of IL-2 and the modes of deliver of IL-2 may more closely mimic physiological conditions.
  • Another method that provides for the local delivery of IL-2 involves the use of genetically altered cells.
  • the difficulty with the use of genetically altered cells to treat solid tumors in this way involves the requirement for the in vitro isolation and growth of appropriate tumor cells, the procedure of transferring genes and selecting for transfectants, and the reinfusion of these genetically altered cells in a safe way. Since naturally occurring tumors often comprise cells of different levels of differentiation, the outgrowth of cells in culture may not fully represent the tumor cells that exist in the patient. Moreover, not all tumors give growing cells in culture and for tumors that do grow, the in vitro procedure will take considerable time. In addition, therapies based on the transfer of genes require the time consuming and labor intensive procedures of transfer of genes and selection for transfectants.
  • the present invention is advantageous as cell growth is not essential for adsorption of cytokine to the surface and adsorption does not entail the introduction of exogenous genes into the patient.
  • Figures 1A and IB present histograms showing IL-2 adsorption to K562 cells immediately after adsorption and after 2 days at 37°C.
  • the histograms with the area under the curves filled in represent control K562 cells without any IL-2 in the medium and the histograms with the area under the curves open represent K562 cells incubated with IL-2.
  • the x axis represents increasing fluorescence intensity on a log scale indicating more IL-2 adsorption the further to the right.
  • the y axis represents the number of cells.
  • Figure 2 is a graph comparing the amount of thymidine incorporation over time for peripheral blood mononuclear cells exposed to JY stimulators not pre-adsorbed with IL-2 (solid circles) and cultured JY stimulators that were pre- adsorbed with IL-2 (solid squares) .
  • the y axis represents tritiated thymidine incorporation (dpm x 1000) .
  • the x axis represents days of incubation.
  • Figure 3 is a graph comparing the amount of thymidine incorporation over time for peripheral blood mononuclear cells exposed to K562 stimulators not pre-adsorbed with IL-2 (solid circles) and K562 stimulators that were pre- adsorbed with IL-2 (solid squares) .
  • the y axis represents tritiated thymidine incorporation (dpm x 1000) .
  • the x axis represents days of incubation.
  • Figure 4 is a graph comparing the amount of thymidine incorporation for IL-2 receptor positive T cells exposed to K562 cells pre-incubated with various concentrations of IL-2 or soluble IL-2.
  • Solid hexagons represent T cells incubated with soluble IL-2, 20 pM.
  • Solid diamonds represent K562 cells not incubated with IL-2.
  • Solid triangles (down) represent K562 cells pre-incubated with 250 nM IL-2.
  • Solid triangles (up) represent K562 cells pre-incubated with 500 nM IL-2.
  • Solid squares represent K562 cells pre-incubated with 1000 nM IL-2.
  • Solid circles represent K562 cells pre-incubated with 2000 nM IL-2.
  • the y axis represents tritiated thymidine incorporation (dpm x 1000) .
  • the x axis represents days of incubation.
  • Figure 5A and 5B present histograms showing IL-2 adsorption to dendritic cells.
  • the cells were freshly isolated.
  • the cells were cultured for 2 days at 37°C.
  • the histograms with the area under the curves filled in represent dendritic cells not incubated with IL-2 and the histograms with the area under the open curve represent dendritic cells incubated with IL-2 prior to staining with anti-IL-2 antibodies.
  • the x axis represents increasing fluorescence intensity on a log scale indicating more IL-2 adsorption the further to the right.
  • the y axis represents the number of cells.
  • the present invention is directed to methods for cellular modulation with a focus on cells used for indu ⁇ cing or enhancing an immune response and involves cytokine adsorbed antigen presenting cells, their methods of pro ⁇ duction and use.
  • the method is applicable to, but not restricted to, clinical situations that require immuno- stimulation, such as tumor immunotherapy and vaccination.
  • the present invention is predicated on the discovery of the utility of adsorbing cytokine to the cell surface of an antigen bearing cell. This technology utilizes the self-associative properties of the molecule which greatly enhance the capacity of cytokine to adsorb to cell surfaces. The presence of protein surrounding the cells after injection favor the slow dissolution and release of the IL-2.
  • cytokine IL-2 2
  • IL-2 adsorbed to an antigen presenting cell induces a more powerful proliferative response than the same antigen presenting cell without adsorbed IL-2.
  • the delivery of IL-2 to a cell surface is predicated upon the discovery of the capability of cell surfaces to load IL-2, taking into account the propensity of the IL-2 molecule to self- associate upon binding to the surface. Self-association allows for large amounts of IL-2 to be localized to the cell surface where the antigen is also present.
  • the present invention may involve adsorbing cytokine to the surface of cells in vitro.
  • a pharmacologically active cytokine composition comprises an cytokine peptide that acts to enhance the immune response of cells by binding to specific surface receptors on the immune cell.
  • a broad array of different IL-2 muteins can be used to mediate these effects.
  • Adsorption of cytokine to the cell surface may be accomplished by incubating high concentrations of cytokine with the desired cell, either in the presence or absence of protein.
  • the IL-2 should be a form of the molecule that self- associates such as the native form. Modifications that enhance self-association can be used for adsorption.
  • the cytokine Upon inoculating an individual with the cell possessing surface adsorbed cytokine, the cytokine is slowly released from the cell so that local concentrations can be maintained for a long period at a high level.
  • IL-2 can be readily adsorbed to the surface of cells, especially peripheral blood antigen presenting cells
  • IL-2 dendritic cells, monocytes, and B lymphocytes
  • the IL-2 in a biologically active form is gradually released over days in culture. These cells do not express the a chain of the IL-2 receptor and thus adsorption occurs by an ⁇ * chain independent mechanism. All cells do not have the capacity to adsorb IL-2 via this a chain independent mechanism. Red blood cells, several different tumor lines, and freshly isolated peripheral blood T lymphocytes and natural killer cells are unable to adsorb the cytokine.
  • the amount of IL-2 adsorbed is estimated to be approximately 50-100,000 molecules per cell. The amount can be varied by incubating the cell with various concen ⁇ trations of IL-2. As few as 100 cells with adsorbed IL-2 can initiate significant proliferation in IL-2 receptor positive cells when co-cultured. IL-2 adsorbed to cells that do not possess the o. chain of the receptor complex cannot be removed by acid treatment with pH 2.5 medium. IL-2 adsorbed to cells through the c. chain can be removed by treatment with acid, pH 4.0.
  • the incubation procedure is believed to work because IL-2 self-associates upon adsorption to cells and thus, antigen presenting cells are preloaded with increased amounts of the cytokine (IL-2 or any other cytokine) .
  • Self-association is a naturally occurring event for IL-2 and thus there is no need to do anything to make the self-association occur.
  • Noncovalent self-association of IL-2 has been demonstrated by a number of different methods (T. Arakawa et al., Bioche . , 25:8274 (1982); J. Fleischmann et al. , Biochem . Biophys . Res . Commun . , 152:879 (1986) ; and D. Kaplan, Mol . Immunol . , 28:1255 (1991)).
  • Self-association has been observed in gel filtration chromatography and in fluorescence quenching which has shown that the K d of self- association of 600 nM (J. Fleischmann et al. , Biochem. Biophys . Res . Commun . , 152:879 (1986)) .
  • the classical IL-2 bioassay does not distinguish among self-associated and non-self-associated cytokine.
  • IL-2 receptor positive cells are pulsed with a source of IL-2 in serum- containing medium for 1 hour at 4°C and then they are plated in icrotiter wells and thymidine incorporation is assessed every day for 1 week.
  • Results indicate that concentrations of IL-2 in the self-associating range, greater than 400 nM, give more proliferation in this assay than concentrations that give negligible self-association, for instance 100 nM, in the prolonged proliferation after pulse assay.
  • these two concentrations are indistinguishable (C. Bergmann et al . , Cytokine, 4:192 (1992)) .
  • IL-2 IL-2 spontaneously forms noncovalent self- associations. This characteristic has not been considered in designing the therapeutic protocols.
  • the present invention uses this property for modifying and regulating the therapeutic responses.
  • This invention encompasses the adsorption of cytokine to an antigen presenting cell and administration of the antigen presenting cell with cytokine adsorbed to a patient. Selection of the antigen presenting cell and the particular cytokine to be absorbed, is based on the disease to be treated. For example treatment of a particular type of cancer entails isolation of tumor cells of the cancer, irradiation of these cells to prevent growth, and adsorption with IL-2. Inoculation of these IL-2 adsorbed tumor cells back into the patient acts to induce or enhance an immune response to the tumor and results in tumor regression. Immunodeficient patients, such as those infected with Human Immunodeficiency Virus (HIV) , do not respond well to vaccines.
  • HIV Human Immunodeficiency Virus
  • HLA-matched irradiated Epstein-Barr virus transformed B cells, non- transformed activated or nonactivated B cells, activated or nonactivated monocytes or dendritic cells pulsed with appropriate antigens such as influenza or tetanus toxid peptides are used for IL-2 adsorption. Inoculation of these cells into immunodeficient patients will enhance their immune responsiveness to the antigens presented.
  • the invention can be utilized to enhance the immune response to any particular antigen by pulsing an antigen presenting cell with a particular antigen and then loading onto that cell the appropriate cytokine. Isolation of antigen presenting cells, culturing of cells, irradiation and pulsing with antigen are practices well known and routine in the art.
  • the antigen presenting cells After adsorption of cells with cytokine, the antigen presenting cells are washed in sterile medium and adjusted to an appropriate cell concentration. The cell suspension is injected into an appropriate site via standard procedures. Administration of antigen presenting cells with adsorbed cytokine will be intradermal, subcutaneous, or intramuscular and is conducted in a manner familiar to those who practice the art.
  • T cells are isolated and cultured in the presence of a particular antigen (e.g. , virus or tumor) so as to induce proliferation. Such techniques are known and routine in the art. These T cells can be loaded with cytokine (e.g. , IL-2 as disclosed in Bergmann et al. 4 Cytokine 192 (1992) and re-infused into patients for therapeutic purposes.
  • cytokine e.g. , IL-2 as disclosed in Bergmann et al. 4 Cytokine 192 (1992
  • cytokine a cytokine
  • a functional derivative retains at least a portion of the function of the cytokine, for example binding activity, or the ability to enhance an immune response which permits its utility in accordance with the present invention.
  • a “chemical derivative” of the cytokine contains additional chemical moieties not normally a part of the protein. Covalent modifications of the cytokine are included within the scope of this invention. Such modifi- cations may be introduced into the molecule by reacting targeted amino acid residues of the cytokine with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
  • Such derivatized moieties may improve the stability, solubility, adsorption, biological half life, and the like.
  • the moieties may alternatively eliminate or attenuate any undesirable side effect of the cytokine and the like.
  • Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences. 18th ed. , Mack Publishing Co., Easton, PA (1990) .
  • fragment is used to indicate a polypeptide derived from the amino acid sequence of the cytokine having a length less than the full-length cytokine from which it has been derived.
  • a fragment may, for example, be produced by proteolytic cleavage of the full- length cytokine.
  • the fragment is obtained recombinantly by appropriately modifying the DNA sequence encoding the proteins to delete one or more amino acids at one or more sites of the C-terminus, N-terminus, and/or within the native sequence. It is understood that such fragments may retain one or more characterizing portions of the native cytokine. Examples of such retained charac ⁇ teristics include: substrate specificity; interaction with other molecules in the intact cell; regulatory functions; or binding with an agent specific for the native cytokine, or an epitope thereof.
  • cytokine comprising at least one "variant" polypeptide which either lack one or more amino acids or contain additional or sub ⁇ stituted amino acids relative to the native cytokine.
  • the variant may be derived from a naturally occurring cytokine component by appropriately modifying the protein DNA coding sequence to add, remove, and/or to modify codons for one or more amino acids at one or more sites of the C- terminus, N-terminus, and/or within the native sequence. It is understood that such variants having added, substi ⁇ tuted and/or additional amino acids retain one or more characterizing portions of the native cytokine, as described above.
  • a functional derivative of cytokines comprising proteins with deleted, inserted and/or substituted amino acid residues may be prepared using standard techniques well-known to those of ordinary skill in the art.
  • the modified components of the functional deriva- tives may be produced using site-directed mutagenesis techniques (as exemplified by Adelman et al. , DNA 2:183
  • nucleotides in the DNA coding the sequence are modified such that a modified coding sequence is produced, and thereafter expressing this recombinant DNA in a prokaryotic or eukaryotic host cell, using techniques such as those described above.
  • components of functional derivatives of cytokines with amino acid deletions, insertions and/or substitutions may be conve ⁇ niently prepared by direct chemical synthesis, using methods well-known in the art.
  • the functional derivatives of the cytokines typically exhibit the same qualitative biological activity as the native cytokines.
  • K562 cells a cultured erythroleukemia tumor line, do not express the a chain of the IL-2 receptor.
  • Cells were incubated with 2000 nM IL-2 for 1 hour at 4°C. After incubation, cells were washed and analyzed for IL-2 binding by utilizing specific anti-IL-2 antibodies and a fluoresceinated second antibody.
  • the histogram in Figure 1A presents an analysis of the cells immediately after adsorption and the histogram in Figure IB presents an analysis of the cells after 2 days of incubation at 37°C. This experiment indicates that IL-2 can be loaded onto cells via an alpha chain independent mechanism and that IL-2 is released from the loaded cells over time.
  • JY cells which are positive for both MHC class I and II, are usually excel ⁇ lent stimulators when 10,000 cells are used for stimu ⁇ lation. The addition of such a small number of untreated JY cells (250 cells) is insufficient to stimulate a proli erative response, but IL-2 adsorption converts these small numbers of cells into powerful stimulators (see Figure 2) .
  • K562 cells which are MHC class II negative, are poor stimulators at any concentration, but IL-2 adsorption converts these cells into powerful stimulators (see Figure 3) Therefore, the presence of IL-2 enhanced responsive- ness to an antigen presenting cell that otherwise is nonstimulatory.
  • Example 3 Adsorption of Cells With IL-2 Enhances Proliferation of IL-2 Receptor Positive T Cells
  • K562 cells were incubated with 2000 nM, 1000 nM, 500 nM, 250 nM of IL-2 or no IL-2 for 1 hour at 4°C. After washing the cells were irradiated and 10 4 of these cells were added to cultures of IL-2 receptor positive T cells. Cultures of IL-2 receptor positive T cells were also incubated with 2 pM of soluble IL-2 in the place of K562 cells. Approximately 20 pM of soluble IL-2 is equivalent to 10 4 K562 cells pre-incubated with 500 nM IL-2. IL-2 driven proliferation of the T cells was determined for 4 days by incorporation of tritiated thymidine. The results (see Figure 4) demonstrate that cell adsorbed IL-2 can mediate IL-2 bioactivity in culture.
  • Dendritic cells were isolated from human peripheral blood mononuclear cells (PBMC) .
  • PBMC peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • IL-2 Binding of IL-2 was accomplished using 2000 nM in 10% fetal bovine serum in phosphate buffered saline as previously described in Example 1. Cells were assayed for IL-2 binding as in Example 1. This experiment indicates that IL-2 is bound to both freshly isolated dendritic cells (Fig. 5A) and cultured dendritic cells (Fig. 5B) .
  • Other embodiments are within the following claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé permettant d'améliorer une réaction immunitaire. Il comprend l'étape consistant à exposer une cellule immune à une cellule présentant un antigène et sur laquelle de la cytokine est adsorbée.
PCT/US1995/013895 1994-10-31 1995-10-27 Procedes et produits permettant d'ameliorer les reactions immunitaires WO1996013275A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33241894A 1994-10-31 1994-10-31
US08/332,418 1994-10-31

Publications (2)

Publication Number Publication Date
WO1996013275A1 true WO1996013275A1 (fr) 1996-05-09
WO1996013275A9 WO1996013275A9 (fr) 1996-08-22

Family

ID=23298146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013895 WO1996013275A1 (fr) 1994-10-31 1995-10-27 Procedes et produits permettant d'ameliorer les reactions immunitaires

Country Status (1)

Country Link
WO (1) WO1996013275A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001807A1 (fr) * 1997-02-07 2000-05-24 Fordham University Immunotherapie adoptive utilisant des complexes proteines de choc thermique/proteines de stress-peptides pour la prevention/le traitement du cancer ou des maladies infectieuses
WO2013102193A1 (fr) * 2011-12-29 2013-07-04 Trustees Of Tufts College Fonctionnalisation de biomatériaux pour commander la régénération et des réponses à une inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005262A1 (fr) * 1990-09-14 1992-04-02 The John Hopkins University Procedes et compositions pour la therapie et la potentialisation genetiques de l'immunite antitumorale
WO1993007906A1 (fr) * 1991-10-25 1993-04-29 San Diego Regional Cancer Center Therapie du cancer par le gene de la lymphokine
US5270038A (en) * 1992-01-23 1993-12-14 Board Of Regents, The University Of Texas System Tumor necrosis factor receptors on microorganisms
EP0611263A2 (fr) * 1993-02-10 1994-08-17 CELLIFE BIOTECNOLOGIE PER LA VITA S.r.l. Méthode de culture "in vitro" de cellules til

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005262A1 (fr) * 1990-09-14 1992-04-02 The John Hopkins University Procedes et compositions pour la therapie et la potentialisation genetiques de l'immunite antitumorale
WO1993007906A1 (fr) * 1991-10-25 1993-04-29 San Diego Regional Cancer Center Therapie du cancer par le gene de la lymphokine
US5270038A (en) * 1992-01-23 1993-12-14 Board Of Regents, The University Of Texas System Tumor necrosis factor receptors on microorganisms
EP0611263A2 (fr) * 1993-02-10 1994-08-17 CELLIFE BIOTECNOLOGIE PER LA VITA S.r.l. Méthode de culture "in vitro" de cellules til

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERGMANN C.A ET AL: "Cytometrically detected specific binding of interleukin 2 to cells", CYTOKINE, vol. 4, no. 3, PHILADELPHIA, pages 192 - 200 *
CRUM, E.D. ET AL: "In vivo activity of solid phase interleukin 2", CANCER RESEARCH, vol. 51, PHILADELPHIA, pages 875 - 879 *
IVAN M. ROITT ET AL: "ENCYCLOPEDIA OF IMMUNOLOGY", ACADEMIC PRESS, LONDON *
KAPLAN, D.R.: "Solid phase interleukin 2", MOLECULAR IMMUNOLOGY, vol. 28, no. 11, OXFORD, pages 1255 - 1261 *
LOPEZ M. ET AL: "Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study", JOURNAL OF IMMUNOTHERAPY, vol. 11, NEW YORK, pages 209 - 217 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001807A1 (fr) * 1997-02-07 2000-05-24 Fordham University Immunotherapie adoptive utilisant des complexes proteines de choc thermique/proteines de stress-peptides pour la prevention/le traitement du cancer ou des maladies infectieuses
EP1001807A4 (fr) * 1997-02-07 2002-07-31 Univ Fordham Immunotherapie adoptive utilisant des complexes proteines de choc thermique/proteines de stress-peptides pour la prevention/le traitement du cancer ou des maladies infectieuses
WO2013102193A1 (fr) * 2011-12-29 2013-07-04 Trustees Of Tufts College Fonctionnalisation de biomatériaux pour commander la régénération et des réponses à une inflammation

Similar Documents

Publication Publication Date Title
Gabrilovich et al. Dendritic cells in antitumor immune responses: I. Defective antigen presentation in tumor-bearing hosts
KR100603075B1 (ko) Ｍｈｃ 클래스 ⅱ 리간드의 예방접종을 위한 항항원체로의이용과 ｌａｇ-3의 암 치료에의 이용
US11407795B2 (en) Peptides and methods for the treatment of diabetes
WO2007067683A2 (fr) Procédés et compositions permettant d'étendre des lymphocytes t régulateurs
JP2975117B2 (ja) 腫瘍疾患の治療のための生ワクチン
DE60128070T2 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
US20110262389A1 (en) Tumor-derived Biological Antigen Presenting Particles
US20120039926A1 (en) Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells
WO1998008947A1 (fr) Amelioration de l'immunisation a l'adn obtenu a l'aide de cytokines
US6596275B1 (en) Monocyte derived cells with immunosuppressive properties, process for their preparation and their uses in pharmaceutical compositions
KR101300905B1 (ko) 백신으로서의 생물학적 활성제와 재조합 마이코박테리움의 조합물
US20040022813A1 (en) Shed antigen vaccine with dendritic cells adjuvant
WO1996013275A1 (fr) Procedes et produits permettant d'ameliorer les reactions immunitaires
WO1996013275A9 (fr) Procedes et produits permettant d'ameliorer les reactions immunitaires
CA2588685A1 (fr) Peptides d'alpha thymosine en tant qu'adjuvants de vaccin anti-cancereux
US20040161806A1 (en) Cells having transferred proteins, and methods of use thereof
US20090060946A1 (en) Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
US20070259006A1 (en) Shed antigen vaccine with dendritic cells adjuvant
WO2002036750A2 (fr) Cellules t a reconnaissance specifique des antigenes mineurs d'histocompatibilite et leurs utilisations dans l'elimination des cellules visees
CN115651913A (zh) 具有抗肿瘤活性的细胞及抑制肿瘤生长的方法
EP0805207A1 (fr) Plasmide d'expression polycistronique pour la réjection de tumeurs
MXPA99012024A (en) Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
MXPA98007775A (en) Methods to induce immune responses in a suj

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES 1/4-4/4;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载